Amneal Pharmaceuticals, Inc.
AMRX
$11.94
-$0.18-1.49%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 11.47% | 11.68% | 3.24% | 5.50% | 18.40% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 11.47% | 11.68% | 3.24% | 5.50% | 18.40% |
| Cost of Revenue | 10.45% | 12.72% | -2.78% | 4.54% | 19.92% |
| Gross Profit | 13.32% | 9.99% | 14.19% | 7.19% | 15.76% |
| SG&A Expenses | 13.74% | 16.11% | 6.70% | 5.06% | 18.15% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | 88.64% | -- | -5,222.00% | -- |
| Total Operating Expenses | 7.26% | 12.65% | 1.17% | 3.55% | 19.37% |
| Operating Income | 46.67% | 5.00% | 16.20% | 18.61% | 10.91% |
| Income Before Tax | 460.57% | -133.87% | 153.42% | 149.64% | 81.65% |
| Income Tax Expenses | 4.41% | -737.07% | 345.02% | 109.03% | -45.13% |
| Earnings from Continuing Operations | 339.00% | 54.22% | 112.13% | 130.14% | 77.78% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -40.22% | -32.32% | -22.24% | -24.67% | -94.89% |
| Net Income | 212.85% | 1,618.59% | 273.99% | 113.31% | 68.49% |
| EBIT | 46.67% | 5.00% | 16.20% | 18.61% | 10.91% |
| EBITDA | 13.54% | -0.30% | 13.27% | 14.56% | 13.25% |
| EPS Basic | 211.17% | 1,600.00% | 268.56% | 113.15% | 75.22% |
| Normalized Basic EPS | 191.71% | 749.32% | 10,266.67% | 310.11% | -675.38% |
| EPS Diluted | 208.97% | 1,600.00% | 260.82% | 113.07% | 75.22% |
| Normalized Diluted EPS | 187.83% | 728.77% | 10,000.00% | 294.38% | -675.38% |
| Average Basic Shares Outstanding | 1.49% | 1.46% | 1.50% | 1.23% | 27.14% |
| Average Diluted Shares Outstanding | 5.89% | 4.88% | 1.07% | 5.43% | 27.14% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |